UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Is self-disturbance in schizophrenia due to inter- and intra-hemispheric white matter dysconnectivity?

Schizophrenia research, 2024-08, Vol.270, p.129-131

Nasrallah, Henry A.

2024

Volltextzugriff (PDF)

Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma

The journal of clinical psychiatry, 2024-05, Vol.85 (2)

Nasrallah, Henry A

2024

Volltextzugriff (PDF)

Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?

Schizophrenia research, 2023-02, Vol.252, p.326-328

Nasrallah, Henry A.

2023

Volltextzugriff (PDF)

Neuroprotective effects of the second generation antipsychotics

Schizophrenia research, 2019-06, Vol.208, p.1-7

2019

Volltextzugriff (PDF)

Re-inventing the schizophrenia syndrome: The elusive “theory of everything”

Schizophrenia research, 2022-04, Vol.242, p.106-108

Nasrallah, Henry A.

2022

Volltextzugriff (PDF)

To change the label of schizophrenia, first revise the construct

Schizophrenia research, 2021-12, Vol.238, p.201-202

Nasrallah, Henry A.

2021

Volltextzugriff (PDF)

Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?

Schizophrenia research, 2018-09, Vol.199, p.31-38

2018

Volltextzugriff (PDF)

Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist

Schizophrenia research, 2019-06, Vol.208, p.217-220

2019

Volltextzugriff (PDF)

Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality

Schizophrenia research, 2018-07, Vol.197, p.69-70

Nasrallah, Henry A.

2018

Volltextzugriff (PDF)

Multiple retinal anomalies in schizophrenia

Schizophrenia research, 2018-05, Vol.195, p.3-12

2018

Volltextzugriff (PDF)

Re-inventing the DSM as a transdiagnostic model: Psychiatric disorders are extensively interconnected

Annals of Clinical Psychiatry, 2021-08 (Volume 33, No. 3)

Nasrallah, Henry

2021

Volltextzugriff (PDF)

Schizophrenia, “just the facts” 4. Clinical features and conceptualization

Schizophrenia research, 2009-05, Vol.110 (1), p.1-23

2009

Volltextzugriff (PDF)

The pro- and con-debate about the at-risk state and early intervention: A commentary

Schizophrenia research, 2021-01, Vol.227, p.18-19

Nasrallah, Henry A.

2021

Volltextzugriff (PDF)

Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study

Journal of psychiatric research, 2013-05, Vol.47 (5), p.670-677

2013

Volltextzugriff (PDF)

Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future

Schizophrenia research, 2010-09, Vol.122 (1), p.1-23

2010

Volltextzugriff (PDF)

Early intervention in psychosis in low- and middle-income countries: Applying the same principles as the developed countries

Asian journal of psychiatry, 2024-09, Vol.99, p.104131, Article 104131

Nasrallah, Henry A.

2024

Volltextzugriff (PDF)

Consequences of misdiagnosis: inaccurate treatment and poor patient outcomes in bipolar disorder

The journal of clinical psychiatry, 2015-10, Vol.76 (10), p.e1328-e1328

Nasrallah, Henry A

2015

Volltextzugriff (PDF)

The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?

Current medical research and opinion, 2022-05, Vol.38 (5), p.773-775

2022

Volltextzugriff (PDF)

It’s time for moonshot thinking in psychiatry

Current Psychiatry, 2022-02, Vol.21 (2), p.8

Nasrallah, Henry A

2022

Volltextzugriff (PDF)

Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics

PloS one, 2013-07, Vol.8 (7), p.e68717

2013

Volltextzugriff (PDF)

Is anosognosia a delusion, a negative symptom, or a cognitive deficit?

Current Psychiatry, 2022-01, Vol.21 (1), p.6

Nasrallah, Henry A

2022

Volltextzugriff (PDF)

Valedictory

Current Psychiatry, 2023-12, Vol.22 (12), p.9

Nasrallah, Henry A

2023

Volltextzugriff (PDF)

I have a dream … for psychiatry

Current Psychiatry, 2021-11, Vol.20 (11), p.12

Nasrallah, Henry A

2021

Volltextzugriff (PDF)

Reversing depression: A plethora of therapeutic strategies and mechanisms

Current Psychiatry, 2022-08, Vol.21 (8), p.4

Nasrallah, Henry A

2022

Volltextzugriff (PDF)

Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse

Schizophrenia research, 2011-04, Vol.127 (1), p.3-13

2011

Volltextzugriff (PDF)

1 – 25 von 658

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(399)
Mit Volltextzugriff
(537)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Psychiatry
(255)
Science & Technology
(247)
Life Sciences & Biomedicine
(244)
Humans
(238)
Schizophrenia
(142)
Male
(128)
Adult
(116)
Female
(110)
Biological And Medical Sciences
(96)
Medical Sciences
(93)
Psychology. Psychoanalysis. Psychiatry
(76)
Middle Aged
(71)
Schizophrenia - Drug Therapy
(71)
Antipsychotic Agents - Therapeutic Use
(69)
Psychopathology. Psychiatry
(69)
Care And Treatment
(64)
Neurosciences & Neurology
(56)
Risk Factors
(52)
Psychoses
(48)
Adult And Adolescent Clinical Studies
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Is self-disturbance in schizophrenia due to inter- and intra-hemispheric white matter dysconnectivity?

Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma

Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?

Neuroprotective effects of the second generation antipsychotics

Re-inventing the schizophrenia syndrome: The elusive “theory of everything”

To change the label of schizophrenia, first revise the construct

Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?

Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist

Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality

Multiple retinal anomalies in schizophrenia

Re-inventing the DSM as a transdiagnostic model: Psychiatric disorders are extensively interconnected

Schizophrenia, “just the facts” 4. Clinical features and conceptualization

The pro- and con-debate about the at-risk state and early intervention: A commentary

Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study

Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future

Early intervention in psychosis in low- and middle-income countries: Applying the same principles as the developed countries

Consequences of misdiagnosis: inaccurate treatment and poor patient outcomes in bipolar disorder

The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?

It’s time for moonshot thinking in psychiatry

Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics

Is anosognosia a delusion, a negative symptom, or a cognitive deficit?

Valedictory

I have a dream … for psychiatry

Reversing depression: A plethora of therapeutic strategies and mechanisms

Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse

Suchergebnisse filtern